

PATIENTS ARE COMPLEX  
CHOOSING A STENT  
SHOULDN'T BE

## INTRODUCING XIENCE Sierra

With the safety you've always relied on and the deliverability you've always wanted, choosing the right stent is now an easier decision.

START

Information contained herein for distribution outside the U.S. only.

Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.


©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A

**Xience Sierra**  
Everolimus Eluting Coronary Stent System



# Best-in-Class Deliverability<sup>1</sup>

XIENCE SIERRA REQUIRES 73% LESS FORCE TO CROSS A LESION THAN SYNERGY AND 64% LESS FORCE THAN RESOLUTE ONYX



1. Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

Information contained herein for distribution outside the U.S. only.

Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A

# Best-in-Class Deliverability<sup>1</sup>

For Even the Most Challenging Lesions<sup>2</sup>


**ULTRA LOW STENT CROSSING PROFILE OF 0.039" FOR EASIER CROSSING ENABLED BY THE NEW STENT DESIGN AND BALLOON TECHNOLOGY<sup>3</sup>**

**XIENCE  
Sierra**  
0.0390"

**XIENCE  
Alpine**  
0.0435"

**SYNERGY**  
0.0393"

**Resolute  
Onyx**  
0.0401"



1. Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.
2. Based on customer feedback on testing XIENCE Sierra in the Synthetic Anatomical Model developed by Abbott.
3. Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5.

**Information contained herein for distribution outside the U.S. only.**


Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A



# Best-in-Class Deliverability<sup>1</sup>

OPTIMIZED MULTI-LINK STENT DESIGN ALLOWS FOR  
TIGHTER CRIMPING AND SMOOTHER CROSSING



NARROWER  
CREST

SLIMMER, MORE  
FLEXIBLE LINKS

1. Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.


**Information contained herein for distribution outside the U.S. only.**

Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A

# Best-in-Class Deliverability<sup>1</sup>

Re-engineered delivery system ensures consistent force transmission for **outstanding pushability**



1. Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.
2. Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5.

**Information contained herein for distribution outside the U.S. only.**

Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.


©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A

# Expanded Treatment Options<sup>1</sup>

UNIQUELY DESIGNED TO POST-DILATE TO 5.5 mm

**5.5 mm**

Maximum  
expansion for  
**3.5 mm and 4.0 mm**



1. Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

**Information contained herein for distribution outside the U.S. only.**


Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A


# Expanded Treatment Options<sup>1</sup>

## ENSURES COATING INTEGRITY<sup>2</sup> EVEN AT MAX EXPANSION

**XIENCE Sierra**  
(3.5 x 18 mm) 25x  
magnification at max  
expansion of 5.5 mm




**XIENCE Sierra**  
(3.5 x 18 mm) 150x  
magnification at max  
expansion of 5.5 mm



**XIENCE Sierra** coating remains intact at maximum post-dilatation expansion of 5.5 mm from 3.5 mm

**SYNERGY**  
(3.5 x 20 mm) 25x  
magnification at max  
expansion of 4.25 mm




**SYNERGY**  
(3.5 x 20 mm) 150x  
magnification at max  
expansion of 4.25 mm




**SYNERGY** coating shows multiple cracks with delamination at its max expansion of 4.25 mm from 3.5 mm

**Resolute Onyx**  
(3.5 x 18 mm) 25x  
magnification at max  
expansion of 4.75 mm



**Resolute Onyx**  
(3.5 x 18 mm) 150x  
magnification at max  
expansion of 4.75 mm



**Resolute Onyx** coating peels off and shows exposed metal at its max expansion of 4.75 mm from 3.5 mm

1. Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.  
2. Test performed by and images on file at Abbott.

Information contained herein for distribution outside the U.S. only.


Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A

# Expanded Treatment Options<sup>1</sup>

PROVIDES UNSURPASSED PRECISION IN PLACEMENT  
AND AVOIDS GEOGRAPHIC MISS

**ZERO** shortening even at  
max expansion to 5.5 mm<sup>2</sup>



1. Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

2. Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (4.0 x 18 mm) n=5, SYNERGY Stent System (4.0 x 20 mm) n=5, Resolute Onyx Stent System (4.5 x 18 mm) n=5.

**Information contained herein for distribution outside the U.S. only.**


Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A



# Unparalleled Safety<sup>1</sup>

## XIENCE SHOWS CONSISTENTLY LOW STENT THROMBOSIS RATES IN COMPLEX PATIENTS<sup>2-7</sup>



NOTE: Data differences depicted between these trials may not be statistically significant or clinically meaningful and different clinical trials may include differences in the patient populations.

1. XIENCE showed significant benefit compared to several DES and composite BMS in multiple large scale meta-analyses and other RCTs. Source: Palmerini, et al. *The Lancet*. 379:9824, 14-20 April 2012, pp. 1393-1402; Bangalore S, et al. *Circ Cardiovasc Interv*, Aug 6, 2013. doi: 10.1161/circinterventions.113.000415; Valgimigli, Effects of Cobalt-chromium Everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014; Serruys, PW, et al. RESOLUTE All Comers Trial, *NEJM* 2010. Published online June 16, 2010; Fajadet, J., et al. PLATINUM PLUS 30-day Poster, TCT 2012. 2. Teeuwen, K. "Hybrid Sirolimus-eluting Stents with Biodegradable Polymer versus Everolimus eluting Stents with Durable Polymer in Chronic Total Occlusions (PRISON IV)." Presented Nov. 2, 2016 at TCT. 3. U Kaul. "Last Word on DES in Diabetics: Two Year TUXEDO Outcomes." Presented on Oct. 30, 2016 at TCT. 4. de Belder A, et al. XIMA Trial. *JACC*. 2014;63:1371-1375. 5. Stone, G. "EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease." Presented Oct. 31, 2016 at TCT. 6. Lam, M. Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and XIENCE V stents in the randomized TWENTE trial. *American Heart Journal*. Vol 169: No 1, Jan 2015. 7. M. Sabaté. Everolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction. Five-year results of the EXAMINATION Trial. ESC 2015.

Information contained herein for distribution outside the U.S. only.

Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A



# Ordering Information

New sizes

STENT DIAMETER	LENGTH								POST-DILATATION LIMIT
	8 mm	12 mm	15 mm	18 mm	23 mm	28 mm	33 mm	38 mm	
2.0 mm	1500200-08	1500200-12	1500200-15	1500200-18	1500200-23	1500200-28	1500200-33	1500200-38	3.75 mm
2.25 mm	1500225-08	1500225-12	1500225-15	1500225-18	1500225-23	1500225-28	1500225-33	1500225-38	3.75 mm
2.5 mm	1500250-08	1500250-12	1500250-15	1500250-18	1500250-23	1500250-28	1500250-33	1500250-38	3.75 mm
2.75 mm	1500275-08	1500275-12	1500275-15	1500275-18	1500275-23	1500275-28	1500275-33	1500275-38	3.75 mm
3.0 mm	1500300-08	1500300-12	1500300-15	1500300-18	1500300-23	1500300-28	1500300-33	1500300-38	3.75 mm
3.25 mm	1500325-08	1500325-12	1500325-15	1500325-18	1500325-23	1500325-28	1500325-33	1500325-38	3.75 mm
3.5 mm	1500350-08	1500350-12	1500350-15	1500350-18	1500350-23	1500350-28	1500350-33	1500350-38	5.50 mm
4.0 mm	1500400-08	1500400-12	1500400-15	1500400-18	1500400-23	1500400-28	1500400-33	1500400-38	5.50 mm

## STENT SPECIFICATIONS

Stent Design	<b>MULTI-LINK, 3-3-3, Nonlinear Link</b>	
Stent Material	<b>L-605 Cobalt Chromium</b>	
Drug	<b>Everolimus</b>	
Drug Dose	<b>1 µg/mm<sup>2</sup></b>	
Polymer	<b>Fluorinated Copolymer</b>	
Strut Thickness	<b>0.0032"</b>	
MRI Compatibility	<b>MR Conditional (see IFU for specific conditions)</b>	
Shortening	<b>0% (nominal expansion)</b>	
Post-Dilatation Limit	<b>Sizes</b>	<b>Post-Dil Limit</b>
	<b>2.0-3.25 mm</b> <b>3.5-4.0 mm</b>	<b>3.75 mm</b> <b>5.5 mm</b>

## DELIVERY SYSTEM SPECIFICATIONS

Nominal Pressure	<b>9 atm for 2.0-2.5 mm;</b> <b>12 atm for 2.75-4.0 mm</b>	
Rated Burst Pressure	<b>16 atm for All Diameters</b>	
Shaft Measurements	<b>Proximal</b> <b>2.1F/0.71 mm</b>	<b>Distal</b> <b>2.7F/0.89 mm</b>
Min. GC/Sheath Diameter	<b>5F/0.056"/1.42 mm</b>	
Balloon Material	<b>Pebax 72D</b>	
Crossing Profile	<b>0.039" (3.0 x 18 mm)</b>	
Tip Entry Profile	<b>0.017" (3.0 x 18 mm)</b>	
Working Catheter Length	<b>145 cm</b>	

Information contained herein for distribution outside the U.S. only.

Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A



Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product carton (when available), at [efu.abbottvascular.com](http://efu.abbottvascular.com) or at [Manuals.sjm.com](http://Manuals.sjm.com) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. **Information contained herein for distribution outside the U.S. only.** Check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

Tests performed by and data on file at Abbott. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

**Abbott International BVBA**

Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

XIENCE Alpine, XIENCE Sierra, and XIENCE V are trademarks of the Abbott Group of Companies. Resolute Onyx is a trademark of Medtronic Inc.

SYNERGY is a trademark of Boston Scientific Corporation or its affiliates.

Pebax is a trademark of Arkema France.

[www.Vascular.Abbott](http://www.Vascular.Abbott)

©2017 Abbott. All rights reserved. AP2944678-OUS Rev. A

